Last $9.65 USD
Change Today +0.03 / 0.31%
Volume 2.2M
PDLI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

pdl biopharma inc (PDLI) Snapshot

Open
$9.62
Previous Close
$9.62
Day High
$9.70
Day Low
$9.54
52 Week High
09/2/14 - $10.26
52 Week Low
02/5/14 - $7.38
Market Cap
1.6B
Average Volume 10 Days
2.3M
EPS TTM
$1.73
Shares Outstanding
160.6M
EX-Date
12/3/14
P/E TM
5.6x
Dividend
$0.60
Dividend Yield
6.22%
Current Stock Chart for PDL BIOPHARMA INC (PDLI)

Related News

No related news articles were found.

pdl biopharma inc (PDLI) Related Businessweek News

No Related Businessweek News Found

pdl biopharma inc (PDLI) Details

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

10 Employees
Last Reported Date: 03/3/14
Founded in 1986

pdl biopharma inc (PDLI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.2M
Chief Financial Officer and Vice President
Total Annual Compensation: $323.2K
Vice President, General Counsel and Secretary
Total Annual Compensation: $659.7K
Chief Accounting Officer and Controller
Total Annual Compensation: $105.0K
Deputy General Counsel and Assistant Secretar...
Total Annual Compensation: $509.6K
Compensation as of Fiscal Year 2013.

pdl biopharma inc (PDLI) Key Developments

PDL BioPharma, Inc. Announces Revenue Guidance for the Third Quarter Ending September 30, 2014

PDL BioPharma, Inc. announced revenue guidance for the third quarter ending September 30, 2014. For the period, the company expected revenue of approximately $165 million as compared with actual revenue of $100.2 million for the third quarter of 2013, an approximate 65% increase.

PDL BioPharma, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014

PDL BioPharma, Inc. reported unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenues increased approximately 10% to $162.8 million from $148.5 million in the second quarter of 2013. Revenues for the second quarter of 2014 include royalty payments from PDL's licensees to the Queen et al. patents, net royalty payments from Depomed, the change in fair value of the Depomed asset, and interest revenue from notes receivable debt financings to late stage healthcare companies. The revenue growth in the second quarter of 2014 is offset by the timing differences of a flat royalty rate on the Genentech related products in 2014 versus a tiered rate in 2013. Net income was $92.1 million, or $0.52 per diluted share, as compared with net income in the second quarter of 2013 of $93.7 million, or $0.62 per diluted share. Operating income was $155,832 million against $141,737 million a year ago. Income before income taxes was $146,056 million against $135,746 million a year ago. The company announced a change from the previous reporting and in recognition of transitioning business model to acquire new revenue-generating assets, it reclassified $12.6 million of interest income in the quarter ended June 30, 2014, related to interest from notes receivable to interest revenue. This compares to $4.9 million in interest revenue for the second quarter of 2013. For the six months, the company's total revenues increased 23% to $299.6 million, compared with $244.1 million for the first six months of 2013. The increase for the six month period of 2014 over 2013 is primarily driven by the addition of the royalty payments from PDL's purchase of Depomed's diabetes-related royalties, increased royalties in the first two quarters of 2014 related to sales of Xolair(R), Kadcyla(R), Perjeta(R), and Actemra(R), along with a higher fixed royalty rate in 2014 over the blended fixed and tiered 2013 rate, a $13.0 million increase in interest revenue related to acquisitions of new revenue generating assets, and a $5.0 million retroactive payment in first quarter of 2014 related to the settlement agreement with Genentech, offset by a higher foreign exchange loss and higher rebate paid to Novartis AG for Lucentis. Net income was $164.9 million, or $0.94 per diluted share, as compared with net income in the first six months of 2013 of $147.2 million, or $0.96 per diluted share. Operating income was $288,054 million against $230,146 million a year ago. Income before income taxes was $261,660 million against $218,245 million a year ago. Net cash provided by operating activities was $146,153 million against $162,709 million a year ago.

PDL BioPharma, Inc. Declares Regular Quarterly Dividend

on January 29, 2014, PDL BioPharma, Inc. board of directors declared regular quarterly dividends of $0.15 per share of common stock, payable on March 12, June 12, September 12 and December 12 of 2014 to all stockholders who own shares of pdl on march 5, June 5, September 5 and December 5 of 2014, the record dates for each of the dividend payments, respectively. on June 12, 2014, the company paid the second quarterly dividend to stockholders of record totaling $24.0 million using earnings generated in the second quarter of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDLI:US $9.65 USD +0.03

PDLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €8.50 EUR +0.19
BioInvent International AB kr3.25 SEK 0.00
Genmab A/S kr233.40 DKK +1.70
XOMA Corp $4.57 USD +0.06
View Industry Companies
 

Industry Analysis

PDLI

Industry Average

Valuation PDLI Industry Range
Price/Earnings 5.8x
Price/Sales 3.5x
Price/Book 5.2x
Price/Cash Flow 5.5x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDL BIOPHARMA INC, please visit www.pdl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.